Skip to main content

Tacrolimus now funded for face eczema

Use of tacrolimus 0.1% and pimecrolimus 1% for treatment of flares of moderate to severe atopic dermatitis and for maintenance and prevention in patients with a high frequency of atopic dermatitis exacerbations, i.e. 4 or more times per year.1 They are particularly useful for the eyelids and face where skin atrophy is a risk.  Neither product causes skin atrophy. They both need approval by a Dermatologist or Pediatrician.

Tacrolimus 0.1% is currently indicated for patients aged 16 and over while pimecrolimus 1% cream is indicated from age 3 months. However, off-label (OL) use of tacrolimus down to 3 months has been effective without significant side effects. OL use includes vitiligo in hair bearing areas. If no improvement after 8 weeks stop. Other OL use is psoriasis on the face.


  1. Tacrolimus now funded for face eczema

Click the button below to be added to our mailing list for Gems and updates.

Join our email list